The FDA placed Biohaven’s ion channel program BHV-7000 on partial clinical hold, Biohaven disclosed. An epilepsy study was paused after regulators requested additional information about preclinical safety, marking another regulatory setback for the company’s pipeline. For biotech teams, partial holds typically mean clinical teams can’t proceed as planned until the sponsor responds with specified data or analysis. The company’s disclosure indicates the issue is tied to safety documentation rather than efficacy. The BHV-7000 development program’s pause reduces near-term visibility on timelines for epilepsy stakeholders and may force investors to reassess probability-weighted value across Biohaven’s neurology assets. The immediate industry signal is that ion-channel programs continue to face scrutiny on preclinical toxicology packages before regulators allow full clinical momentum.